ACE2 and COVID-19: Pooled MR estimates showed that VD was not significantly associated with COVID-19 outcomes, whereas ACE2 increased COVID-19 risk (MR odds ratio = 1.10; 95% CI: 1.01–1.19) but did not affect hospitalization or severity of the disease.